Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Luigi Rossi; Giuseppe Cimino; Elisa Gozzi; Marsela Sinjari; Martina Brandi; Serena Ceddia; Antonella Cosimati; Lucrezia Raimondi; Antonella Fontana; Luca Filippi; Oreste Bagni; Gian Paolo Spinelli

doi:10.1159/000514979

Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Case Rep Oncol. 2021 Mar 31;14(1):634-640. doi: 10.1159/000514979. eCollection 2021 Jan-Apr.

Affiliations

¹ UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
² Department of Cellular Biotechnology and Hematology, University of Rome "Sapienza", Rome, Italy.
³ Department of Radiotherapy, Santa Maria Goretti Hospital, Latina, Italy.
⁴ Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.

Abstract

We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.

Keywords: Abiraterone; Bone metastases; Enzalutamide; Metastatic castration-resistant prostate cancer; PSA.

Publication types

Case Reports